Vectors for gene therapy of cardiovascular disease

被引：5
|
作者：
Dedieu J.-F. [1 ]
Mahfoudi A. [1 ]
Le Roux A. [2 ]
Branellec D. [2 ]
机构：
[1] Vector Development Department, quai Jules Guesde 94403 Vitry-sur-Seine, Rhône-Poulenc Rorer Gencell
[2] Cardiovascular Department, quai Jules Guesde 94403 Vitry-sur-Seine, Rhône-Poulenc Rorer Gencell
来源：
Current Cardiology Reports | 2000年 / 2卷 / 1期
关键词：
Gene Therapy; Gene Transfer; Gene Delivery; Adenoviral Vector; Hexon;
D O I：
10.1007/s11886-000-0024-3
中图分类号：
学科分类号：
摘要：
Several phase I/II clinical trials are currently ongoing in gene therapy of cardiovascular disease. Whereas the indications vary, including peripheral artery disease, ischemic heart disease, post-angioplasty restenosis, and vein graft failure, these trials are mostly based on the use of adenoviral vectors and nonviral vectors. Novel vectors aimed at improving the efficacy and safety of gene delivery in target organs, such as heart, skeletal muscle, vasculature and liver, have been recently generated. Some of them have already been successfully validated in preclinical m odelsof cardiovascular disease. This review focuses on the most recent advances in vector development that could substantially increase the spectrum of cardiovascular pathologies amenable to gene transfer-based treatments. Copyright © 2000 by Current Science Inc.
引用
收藏
页码：39 / 47
页数：8
相关论文
共 50 条
12345